TECX: Tectonic Therapeutic, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 1 sales totaling $12K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-09-30 | Mcnamara Peter | Officer | $12K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-10-29 | Fell below 5% | Aberdeen Group plc | 2.48% | SEC |
Institutional ownership (Q2 2026)
122 institutions reported holding $466.08M of Tectonic Therapeutic, Inc. on Form 13F (111 the quarter before). 24 opened a new position and 11 sold out. Shares held by institutions: +2%.
| Largest holders | Shares | Value |
|---|---|---|
| FMR LLC | 2,830,378 | $97.29M |
| TCG Crossover Management, LLC | 1,204,891 | $41.42M |
| Aberdeen Group plc | 1,141,824 | $39.25M |
| BlackRock, Inc. | 862,592 | $29.65M |
| First Light Asset Management, LLC | 800,726 | $27.52M |
| BAKER BROS. ADVISORS LP | 607,788 | $20.89M |
| 5AM Venture Management, LLC | 606,660 | $20.85M |
| BRAIDWELL LP | 596,900 | $20.52M |
| VANGUARD CAPITAL MANAGEMENT LLC | 488,805 | $16.80M |
| Vestal Point Capital, LP | 425,000 | $14.61M |
Clinical trial readouts
1 Phase 2 or 3 trials by Tectonic Therapeutic, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-11-24 (est.) | TX000045- Dose A | Pulmonary Hypertension | Phase 2 | 191 | Enrollment complete | NCT06616974 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.